Document is current

Article History

Accepted: 17 November 2024

First Online: 25 November 2024

Declarations

:

: The current analysis is based on results of the MOMENTUM trial. MOMENTUM was done in accordance with the Declaration of Helsinki and the International Council for Harmonisation guidelines on Good Clinical Practice. Institutional review boards or independent ethics committees at each site approved the protocol.

: Written consent was obtained from all individual participants included in the MOMENTUM study.

: Not applicable. All personal data are deidentified.

: Christina Daskalopoulou holds an advisory role within IQVIA and reports grants from GSK during the conduct of this study. Boris Gorsh has been employed by GSK and Daiichi Sankyo during the production of this manuscript and has stock or stock options with both companies. Gerasimos Dumi and Jean Paty are employees of IQVIA. Samineh Deheshi is an employee of GSK. Chad Gwaltney has received consulting fees from IQVIA for this MFSAF evaluation. Catherine Ellis is an employee of GSK and reports stock or stock options. Jun Kawashima is an employee of Sierra Oncology, a GSK company. Ruben Mesa reports consulting fees/honoraria from AbbVie, Blueprint, Bristol Myers Squibb, CTI, Genentech, Geron, GSK, Incyte, MorphoSys, Novartis, Sierra, Sierra Oncology, and Telios. All authors acknowledge medical writing support related to this manuscript, funded by GSK.